TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
880 Winter Street, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 632 % -17%
Debt-to-equity 77 % +23.9%
Return On Equity -61.1 % +10.4%
Return On Assets -34.5 % +17.9%
Operating Margin -689 % -63%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24 M shares
Entity Public Float 74.5 M USD -99.8%
Weighted Average Number of Shares Outstanding, Basic 94.9 M shares +292%
Weighted Average Number of Shares Outstanding, Diluted 94.9 M shares +292%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.8 M USD -14.5%
Research and Development Expense 91.2 M USD +36.4%
General and Administrative Expense 25.7 M USD +8.65%
Operating Income (Loss) -102 M USD -39.4%
Net Income (Loss) Attributable to Parent -96.8 M USD -33.3%
Earnings Per Share, Basic -0.75 USD/shares +75.1%
Earnings Per Share, Diluted -0.75 USD/shares +75.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 141 M USD +47%
Marketable Securities, Current 22.3 M USD
Accounts Receivable, after Allowance for Credit Loss, Current 31.9 M USD
Assets, Current 165 M USD +63.2%
Property, Plant and Equipment, Net 7.2 M USD -20.2%
Operating Lease, Right-of-Use Asset 62.2 M USD +7.46%
Assets 241 M USD +38.7%
Accounts Payable, Current 2.12 M USD -23.4%
Employee-related Liabilities, Current 2.23 M USD -10.2%
Liabilities, Current 31.5 M USD +124%
Operating Lease, Liability, Noncurrent 58.2 M USD +11.9%
Other Liabilities, Noncurrent 12 K USD -87.6%
Liabilities 118 M USD +23.3%
Retained Earnings (Accumulated Deficit) -278 M USD -53.5%
Stockholders' Equity Attributable to Parent 123 M USD +57.6%
Liabilities and Equity 241 M USD +38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3 M USD -24.1%
Net Cash Provided by (Used in) Financing Activities 258 K USD
Net Cash Provided by (Used in) Investing Activities 36.2 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.15 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146 M USD +44.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 758 K USD +2.02%
Deferred Tax Assets, Valuation Allowance 82.2 M USD +58.6%
Operating Lease, Liability 62.4 M USD +10%
Depreciation 1.25 M USD -16.3%
Payments to Acquire Property, Plant, and Equipment 705 K USD -15.9%
Lessee, Operating Lease, Liability, to be Paid 95.9 M USD +6.92%
Property, Plant and Equipment, Gross 22.3 M USD +9.94%
Operating Lease, Liability, Current 3.34 M USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.5 M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.51 M USD +5.24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.5 M USD +1.57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.9 M USD +35.7%
Deferred Tax Assets, Operating Loss Carryforwards 23.2 M USD -0.81%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.3 M USD +35.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 99.6 M USD +45.9%
Interest Expense 3.76 M USD +0.31%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares